Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity

Acta Neuropathologica

Volumn 91, Issue 5, 1996, Pages 466-474

  Salonen, Tuuli ^a   Haapalinna, Antti ^b   Heinonen, Esa ^b   Suhonen, Jaana ^c   Hervonen, Antti ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Neuroprotection; Neurotoxin; Selegiline; Sympathetic neurons

Indexed keywords

6 HYDROXYTRYPTAMINE; ANTIOXIDANT; CATECHOLAMINE; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

ADRENERGIC NERVE; ADRENERGIC NERVE CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATECHOLAMINE NERVE CELL; CONTROLLED STUDY; DOSE RESPONSE; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MOTONEURON; NERVE FIBER TRANSECTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTGANGLIONIC NERVE; PRIORITY JOURNAL; RAT; SUBMANDIBULAR GLAND; SUPERIOR CERVICAL GANGLION; SYMPATHETIC NERVE CELL;

AGING; ANIMALS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, FLUORESCENCE; MONOAMINE OXIDASE INHIBITORS; OXIDOPAMINE; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, WISTAR; SELEGILINE; SUPERIOR CERVICAL GANGLION; TYROSINE 3-MONOOXYGENASE;

EID: 0029876906     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004010050453     Document Type: Article

References (53)

1. Acheson AL, Zigmond MJ, Stricker EM (1980) Compensatory increase in tyrosine hydroxylase activity in rat brain after intraventricular injections of 6-hydroxydopamine. Science 207: 537-540
2. Alho H, Partanen M, Hervonen A (1983) Microfluorimetric quantification of catecholamine fluorescence in rat sympathetic ganglia. Histochem J 15: 1203-1215
3. Amenta F, Bongram S, Caciel S, Ferrante F, Vaisecchi B, Vega JA (1994) Microanatomical changes in the frontal cortex of aged rats: effect of L-deprenyl treatment. Brain Res Bull 34: 125-131
4. Amenta F, Bongrani S, Cadel S, Ricci A, Valsecchi B, Zeng YC (1994) Neuroanatomy of aging brain. Influence of treatment with L-deprenyl. Ann NY Acad Sci 30: 717: 33-44
5. Angeletti PU, Levi-Monialcini R (1970) Sympathetic nerve cell destruction in newborn mammals by 6-hydroxvdopamine. Proc Natl Acad Sci USA 65: 114-121
6. Ansari KS, Yu PH, Kruck PA, Tatton WG (1993) Rescue of axotomized immature rat facial motoneurons by L-(-)deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13: 4042-4053
7. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO (1994) The effect of a long term (6 months) treatment with (-)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats. Biochem Pharmacol 47: 1333-1338
8. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO (1994) (-)Deprenyl increases activities of Superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci 54: 975-981
9. Chiba K, Trevor A, Castagnoli N (1984) Metabolism of the neurotoxic tertiary amine. MPTP, by brain monoamine oxidasc. Biochem Biophys Res Commun 120: 574-578
10. Cohen G, Pasik B, Cohen B, Leist C, Mytilincou C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of lmethyl-4-phenyl-1.2,3.6-tetrahvdropyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209-210
11. Decker DE, Althaus JS, Buxser SE, Von Voigtlander PF, Rupper PL (1993) Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. Res Commun Chem Pathol Pharmacol 79: 195-208
12. Erankö O (1967)The practical histochemical demonstration of catecholamines bv formaldehyde-induced fluorescence. J R Microsc Soc 87: 259-276
13. Finnegan KT, Skratt JJ, Irwin I, DeLanney LE, Langston WJ (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184: 119-126
14. Geiowitz DL, Richardson JS, Wishart TB, Yu PH, Lai CT (1994) Chronic L-deprenyl or L-amphetamine: equal cognitive enhancement, unequal MAO inhibition. Pharmacol Biochem Behav 47: 41-45
15. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine. 6-hydroxydopamine, and related compounds toward c 1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644-653
16. Hallman H, Jonsson GH (1984) Pharmacological modification of the neurotoxic action of noradrenaline neurotoxin DSP-4 on central noradrenaline neurons. Eur J Pharmacol 103: 269-278
17. Heikkila RE, Cohen G (1972) Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine. Mol Pharmacol 8: 241-248
18. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469
19. Heinonen EH, Anttila M, Nyman L, Vuorinen J, Lammintausta R (1993) Desmethylseiegiline. a metabolite of selegiline, is an irreversible inhibitor of MAO-B in human subjects. Neurolosy 43: A156
20. Hemonen EH, Anttila M, Kamani H, Lammintausta R (1994) Pharmacokinetics of selegiline after oral dosing. Abstracts of the 3rd International Congress of Movement Disorders, Orlando, Florida 7-12 November 1994. Mov Disord 9 [Suppl 1]: 248
21. Hervonen A (1971) Development of catecholamine storing cells in human fetal paraganglia and adrenal medulla. Acta Physiol Scand [Suppl] 368
22. Hokfelt T, Fuxe K. Goldstein M, John T (1973) Immunohistochemical iocalization of three catechoiamine synthesizing enzymes: aspects on methodology. Histochemistry 33: 231-254
23. Johnston JP (1961) Some observations upon a new inhibitor of monoamtne oxidase in brain tissue. Biochem Pharmacol 17: 1285-1297
24. Kitani K, Kanai S, Sato Y, Ohta M. Ivy GO, Carrillo M-C (1992) Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci 52: 281-288
25. Kitani K, Kanai S, Carrillo MC, Ivy GO (1994; (-)Deprenyl increases the life span as well as activities of Superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats. Ann NY Acad Sci 30: 717: 60-71
26. Knoll J (1978) The possible mechanism of action of (-)deprenyl in Parkinson's disease. J Neural Transm 43: 177-198
27. Knoll J (1987) L-(-)Deprenyl (selegiline. Movergan®) facilitates the activity of the nigrostnatal dopaminergic neuron. J Neural Transm [Suppl] 25: 45-66
28. Knoll J (1988) The striatal dopamine dependency of lifespan in male rats. Longevity study with (-)deprenyl. Mech Agina Dev 46: 237-262
29. Knoll J (1989) The pharmacology of selegiline (selegiline). New aspects. Acta Neurol Scand 80: 83-92
30. Knoll J (1993) The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J Neural Transm [Suppl] 40: 69-91
31. Knoll J, Dallo J, Yen TT (1989) Striatal dopamine, sexual activity and lifespan lonaevity of rats treated with (-)deprenyl. Life Sci 45: 525-531
32. Kostrzewa RM (1989) Neurotoxins that affect central and peripheral catecholamine neurons. In: Boulton AA, Baker GB, Juorio AV (eds) Drugs as tools in neurotransmitter research. Humana Press. Clifton, pp 1-48
33. MacDonald E, Sirviö J (1993) Neurotoxins as tools in lesioning experiments. In: Harvey AL (ed) Natural and synthetic neurotoxins. Academic Press, London, pp 1-46
34. Mangoni A, Grassi MP, Frattola L (1991) Effects of an MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol 31: 100-107
35. Marek GJ, Vosmer G, Seiden LS (1990) The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat. Brain Res 516: 1-7
36. Neal BS, Joyce JN (1992) Neonatal 6-OHDA lesions differentially affect striatal D1 and D2 receptors. Synapse 11: 35-46
37. Ogawa N, Asanuma M, Kondo Y, Hirata H, Nishibayashi S, Mon A (1994) Changes in lipid peroxidation, Cu/Zn-superoxide dismutase and its mRNA following an intracerebroventricular injection of 6-hydroxydopamine in mice. Brain Res 646: 337-340
38. Oh C, Murray B, Bhattacharya N. Holland D, Tatton WG (1994) (-)Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J Neurosci Res 38: 64-74
39. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1364-1371
40. Parkinson Study Group (1993) Effects of tocopherol on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183
41. Philips SR (1981) Amphetamine, parahydroxy-amphetamine and beta-phenethylamine in mouse brain and urine after (-)-and (+)deprenvl administration. J Pharm Pharmacol 33: 739-741
42. Piccinin GL, Finali G, Piccirilli M (1990) Neuropsychological effects of selegihne in Alzheimer's type dementia. Clin Neuropharmacol 13: 147-163
43. Reinikainen KJ, Paljärvi L, Halonen T, Malminen O, Kosma VM, Laakso M, Riekkinen PJ (1988) Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging 9: 245-252
44. Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542-545
45. Salo PT, Tatton WG (1992) Deprenyl reduces the deaih of motoneurons caused by axotomy. J Neurosci Res 31: 394-400
46. Sternberger LA (1979) Immunohistochemistry, 2nd edn. Wiley. New York
47. Suhonen J, Koistinaho J, Hervonen A (1990) Survival of both young and aged sympathetic neurons in the adrenal cortex after autotransplantation. Histochemistry 94: 591-595
48. Suhonen J, Koistinaho J, Hervonen A (1991) Histochemistry of sympathetic neurons allotransplanted from young and aged mice to the submandibular gland. Exp Neurol 112: 104-111
49. Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666-672
50. Tekes K, Tóthfalusi L, Gaál J, Magyar K (1988) Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol J Pharmacol Pharm 40: 653-658
51. Zeng YC, Bongrani S, Bronzetti E, Cadel S, Ricci A, Valsecchi B, Amenta F (1994) Influence of long-term treatment with Ldeprenyl on the age-dependent changes in rat brain microanatomy. Mech Ageing Dev 73: 113-126
52. Zhu YS, Jones SB, Burke RE, Franklin SO, Inturrisi CE (1993) Quantitaten of the levels of tyrosine hydroxylase and preproenkephalin mRNAs in nigrostriatal sites after 6-hydroxydopamme lesions. Life Sci 52: 1577-1584
53. Zsilla G, Fóldi P, Held G, Székely AM. Knoll J (1986) The effect of repeated doses of (-)deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol J Pharmacol Pharm 38: 57-67